What Are the 5 A's of Opioid Management?
A practical framework for insurance professionals monitoring opioid therapy outcomes and claim risk.
Published: 4 April 2026
Introduction
As an insurance claims manager, you need practical tools to assess whether opioid therapy is working effectively for your claimants and whether it remains appropriate. The 5 A's of opioid management form a structured framework used across pain medicine, primary care, and workers compensation schemes to evaluate opioid efficacy, safety, and appropriateness.
This framework originated in addiction medicine and has been widely adopted in Australia by WorkSafe, SIRA, and the Faculty of Pain Medicine as a standardized way to monitor patients on long-term opioid therapy. Understanding the 5 A's helps you identify when treatment adjustments are needed and when alternative strategies should be considered.
The 5 A's Framework Explained
1. Analgesia: Pain Relief
Analgesia refers to the degree of pain relief the claimant is experiencing. As a claims manager, this is your primary outcome measure. You should be asking: Is the opioid therapy delivering meaningful pain reduction?
In practice, this means looking for documented pain scores or functional improvements. Common tools include numerical pain rating scales (0-10) or pain scales tied to specific activities. A claimant should demonstrate at least 30% reduction in pain for opioid therapy to be considered effective in most cases.
Red flags for your claims assessment include: pain scores remaining unchanged despite months of opioid therapy, escalating doses with minimal pain improvement, or vague descriptions of relief without measurable outcomes.
2. Activity: Functional Capacity
Activity measures functional improvement and return-to-work capacity. This is critical for your claim management. The goal of pain treatment is not simply to reduce pain, but to enable claimants to resume meaningful activities.
You should expect to see documented improvements in activities of daily living, work capacity, or participation in rehabilitation. This might include increased walking distance, return to work on graduated duties, or improved self-care capacity.
Watch for claimants reporting significant pain relief but showing no functional improvement. This mismatch suggests the treatment may not be addressing the underlying functional barriers or that secondary gain factors may be present.
3. Adverse Effects: Tolerability Profile
Adverse effects encompass all unwanted medication side effects. For long-term opioid therapy, this is a critical claim management issue because side effects often outweigh benefits over time.
Common opioid-related adverse effects include constipation, sedation, cognitive impairment, nausea, and respiratory depression. You need to understand whether the treating provider has implemented strategies to manage side effects. This might include laxatives for constipation, dose reduction, or medication adjustment.
Red flags include: treating providers dismissing side effect complaints, escalating doses without managing existing side effects, or claimants reporting significant impairment from medication effects yet continuing unchanged therapy.
4. Aberrant Behaviour: Safety and Compliance
Aberrant behaviour refers to drug use patterns that fall outside expected therapeutic parameters. This is where your claims management intersects with risk management most directly.
Examples include: early refills, lost prescriptions, requests for dose increases without clinical rationale, visiting multiple prescribers (doctor shopping), concurrent use of other sedating drugs, or positive urine screening for non-prescribed substances.
Australia's real-time prescription monitoring systems (SafeScript in Victoria and other states, QScript in Queensland) help you detect some of these behaviours. However, you should also look for reports from treatment providers about compliance concerns, disputes over prescriptions, or medication-seeking behaviour patterns.
5. Affect: Psychological Status
Affect refers to the claimant's mood and psychological wellbeing. Chronic pain and prolonged opioid therapy are associated with depression, anxiety, and other mental health concerns.
You should expect treating providers to screen for mood disorders using tools like PHQ-9 (depression) or GAD-7 (anxiety). Untreated or worsening depression is a major red flag because it indicates the overall treatment approach may not be working and the claimant may be at increased risk for medication misuse.
Look for documentation of psychological assessment and, where indicated, evidence of concurrent psychological or psychiatric support. Opioid therapy in isolation without addressing psychological factors is unlikely to achieve optimal outcomes.
The 5 A's Monitoring Table
| The "A" | What It Measures | What You Should See | Red Flags for Claims Managers |
|---|---|---|---|
| Analgesia | Pain reduction from baseline | 30%+ documented pain score reduction; pain scores tracked regularly (e.g., 0-10 scale) | No change in pain scores; escalating doses without pain improvement; vague or unmeasured pain statements |
| Activity | Functional improvement and work capacity | Increased activity tolerance; graduated return to work; improved ADL capacity; documented functional gains | Pain reduction claimed but no functional improvement; no documented work progress; unchanged activity levels despite treatment |
| Adverse Effects | Medication side effect burden | Side effects documented and monitored; active management strategies (laxatives, dose adjustment); acceptable side effect profile | Untreated side effects; escalating doses without managing existing effects; claimant reports significant impairment but therapy unchanged |
| Aberrant Behaviour | Compliance and drug-seeking patterns | Consistent prescription use; no duplicate dispensing or early refills; no multiple prescriber visits; negative RTPM checks | Early refills or lost prescriptions; visits to multiple prescribers; positive RTPM flags; concurrent sedating drug use; non-prescribed substances detected |
| Affect | Psychological wellbeing and mood | Mood screening documented (PHQ-9, GAD-7); stable or improving mental health; concurrent psychological support when needed | Depression or anxiety not assessed; worsening mood untreated; no psychological support despite mental health concerns; mood scores indicate significant distress |
Applying the 5 A's to Your Claims Management
Initial Opioid Therapy Assessment
When you receive a claim involving opioid therapy initiation, request documentation addressing all 5 A's from the treating provider. You should see: baseline pain assessment, functional baseline, side effect baseline, screening for substance use or aberrant behaviour risk, and mental health screening. This establishes your benchmarks for measuring progress.
Ongoing Monitoring (3-6 Monthly)
At each monitoring interval, you should receive updates on all 5 A's. Performance across all five measures should show improvement, stability, or documented justification for why specific A's are not improving. If three or more A's show no progress or deterioration, this signals that treatment adjustment may be needed.
Red Flag Scenarios
Certain patterns across the 5 A's should trigger your closer review: Analgesia improving but Activity unchanged (functional barrier not opioid-related); Analgesia improving but Affect worsening (indicating need for mental health support); Aberrant Behaviour emerging with increasing doses (suggesting medication misuse risk); or any A showing consistent deterioration despite escalating opioid doses (indicating treatment failure).
Claims Manager Workflow: When to Request Structured Review
Request a structured medication review from an independent pharmacist when:
- Two or more A's show deterioration over consecutive review periods
- Doses have escalated without corresponding improvements across the 5 A's
- Aberrant behaviour is detected without documented management plan
- Claimant remains on high-dose opioids beyond 12 months with minimal functional gain
- Mental health concerns are present but untreated
An independent pharmacist assessment can evaluate whether current opioid therapy aligns with current best practice guidelines and identify alternative strategies that may be more effective.
Integrating the 5 A's with Australian Guidelines
Australia's opioid prescribing framework is evolving. SIRA (State Insurance Regulatory Authority) guidance, WorkSafe guidelines, and the Faculty of Pain Medicine recommendations all emphasize the importance of structured monitoring against measurable outcomes. The 5 A's framework aligns with these regulatory expectations.
When you challenge opioid therapy decisions or request modifications, framing your questions around the 5 A's gives you credibility with treating providers. Rather than saying "the claimant doesn't need opioids," you're saying "across the 5 outcome measures, I'm not seeing the improvement we'd expect" or "Affect is deteriorating while we're escalating Analgesia doses."
Common Questions About the 5 A's
What if the claimant improves on only 3 of the 5 A's?
That depends on which three. Improvement in Analgesia, Activity, and Adverse Effects with stable Affect and no Aberrant Behaviour represents reasonable progress. However, if Affect is worsening or Aberrant Behaviour is emerging, the overall treatment needs reconsideration even if pain improves.
Should all 5 A's improve simultaneously?
Ideally, yes. In practice, there's often a sequence. Analgesia typically improves first, followed by Activity as pain reduces. Adverse Effects should remain stable or improve as the body adjusts. Aberrant Behaviour should never emerge. Affect often takes longer to improve. By month 6 of therapy, all five should show clear progress or the treatment should be questioned.
How do I discuss the 5 A's with treating providers?
Use language like: "I'm reviewing how the opioid therapy is performing across the five outcome dimensions. Can you provide me with current documentation on pain scores, functional capacity, side effects, any compliance concerns, and mood screening?" This frames the conversation as collaborative assessment rather than gatekeeping.
Ready to implement structured opioid monitoring in your claims management?
IMM's medication review services help insurance professionals assess opioid therapy effectiveness using evidence-based frameworks like the 5 A's. Our pharmacists provide independent clinical assessments that support your claim management decisions.
Explore IMM's Resources for Insurance ProfessionalsConclusion
The 5 A's of opioid management provide you with a structured, evidence-based framework for evaluating whether opioid therapy is working for your claimants. By consistently monitoring Analgesia, Activity, Adverse Effects, Aberrant Behaviour, and Affect, you can have informed conversations with treating providers about whether current treatment is appropriate or whether modifications are needed.
This framework is used across Australian workers compensation schemes, CTP claims, and NDIS medication management. Adopting it in your claims assessment ensures you're applying industry-standard monitoring principles and documenting your clinical rationale for claim decisions.
